- Home
- CFR vs LEGN Comparison
CFR vs LEGN Comparison
Compare CFR & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CFR | LEGN |
|---|---|---|
| Founded | 1868 | 2014 |
| Country | United States | United States |
| Employees | 6008 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 3.6B |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CFR | LEGN |
|---|---|---|
| Price | $153.48 | $19.32 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 15 | 13 |
| Target Price | ★ $173.79 | $46.90 |
| AVG Volume (30 Days) | 398.1K | ★ 1.7M |
| Earning Date | 10-29-2026 | 11-11-2026 |
| Dividend Yield | ★ 2.70% | N/A |
| EPS Growth | ★ 11.84 | N/A |
| EPS | ★ 5.35 | N/A |
| Revenue | ★ $2,235,244,000.00 | N/A |
| Revenue This Year | $3.80 | $39.04 |
| Revenue Next Year | $6.40 | $25.29 |
| P/E Ratio | $28.82 | ★ N/A |
| Revenue Growth | ★ 8.31 | N/A |
| 52 Week Low | $119.00 | $16.24 |
| 52 Week High | $170.80 | $37.50 |
Technical Indicators
Market Signals| Indicator | CFR | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 29.63 | 51.01 |
| Support Level | $133.49 | $17.81 |
| Resistance Level | $170.55 | $20.39 |
| Average True Range (ATR) | 2.84 | 0.77 |
| MACD | -0.76 | 0.25 |
| Stochastic Oscillator | 0.98 | 88.36 |
Price Performance
Historical ComparisonAbout CFR Cullen/Frost Bankers Inc.
Cullen/Frost is a regional US bank with around $54 billion in assets (as of June 2026), and it focuses exclusively on the Texas market. The bank has deep expertise in this market. It has implemented a relationship-based banking approach that has garnered a strong market share in San Antonio. Cullen/Frost is also expanding into Houston, Dallas, and Austin market regions through targeted branch openings rather than acquisitions. The bank's sweet spot is small to medium-sized Texas-based commercial clients.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.